Search strategy

A. Medline

Platform: OvidSP

Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1948 to Present

Date: 23-08-2011

Limits: no limits were used

Methodological filters: Adverse effect filter: Golder, S. et al Developing efficient search strategies to identify reports of adverse effects in Medline and Embase. Health information and libraries journal (2006),23, p3-12

|  |  |
| --- | --- |
| **Line #** | **Terms** |
| 1. |  latent.mp. |
| 2. |  contact\*.mp. |
| 3. |  exp Contact Tracing/ |
| 4. |  exp Antibiotic Prophylaxis/ |
| 5. |  exp Chemoprevention/ |
| 6. |  prevent\*.mp. |
| 7. |  prophyla\*.mp. |
| 8. | or/1-7 |
| 9. |  exp Ethambutol/ |
| 10. |  ethambutol.ti,ab. |
| 11. |  pyrazinamide.mp. or exp Pyrazinamide/ |
| 12. |  streptomycin.mp. or exp Streptomycin/ |
| 13. |  amikacin.mp. or exp Amikacin/ |
| 14. |  kanamycin.mp. or exp Kanamycin/ |
| 15. |  capreomycin.mp. or exp Capreomycin/ |
| 16. |  viomycin.mp. or exp Viomycin/ |
| 17. |  enviomycin.mp. or exp Enviomycin/ |
| 18. |  fluoroquinolones.mp. or exp Fluoroquinolones/ |
| 19. |  levofloxacin.mp. or exp Ofloxacin/ |
| 20. |  moxifloxacin.mp. |
| 21. |  ofloxacin.mp. |
| 22. |  ciprofloxacin.mp. or exp Ciprofloxacin/ |
| 23. |  sparfloxacin.mp. |
| 24. |  thioamides.mp. or exp Thioamides/ |
| 25. |  cycloserine.mp. or exp Cycloserine/ |
| 26. |  opc-67683.mp. |
| 27. |  PA-824.mp. |
| 28. |  thiacetazone.mp. or exp Thioacetazone/ |
| 29. |  p-aminosalicylic acid.mp. or exp Aminosalicylic Acid/ |
| 30. |  para-aminosalicyclic acid.mp. |
| 31. |  ethionamide.mp. or exp Ethionamide/ |
| 32. |  rifabutin.mp. or exp Rifabutin/ |
| 33. |  rifapentine.mp. |
| 34. |  r207910.mp. |
| 35. |  terizidone.mp. |
| 36. |  protionamide.mp. or exp Prothionamide/ |
| 37. |  cilastatin.mp. or exp Cilastatin/ |
| 38. |  TMC207.mp. |
| 39. |  gatifloxacin.mp. |
| 40. |  prothionamide.mp. |
| 41. |  or/9-40 |
| 42. |  ("health care worker" or "health care workers").ti,ab. |
| 43. |  healthy.ti,ab. |
| 44. |  8 or 42 or 43 |
| 45. |  ae.fs. |
| 46. |  de.fs. |
| 47. |  co.fs. |
| 48. |  to.fs. |
| 49. |  safe.ti,ab. |
| 50. |  safety.ti,ab. |
| 51. |  side-effect\*.ti,ab. |
| 52. |  undesirable effect\*.ti,ab. |
| 53. |  treatment emergent.ti,ab. |
| 54. |  tolerability.ti,ab. |
| 55. |  toxicity.ti,ab. |
| 56. |  adrs.ti,ab. |
| 57. |  or/45-56 |
| 58. |  41 and 44 and 57 |
| 59. |  exp Case Reports/ |
| 60. |  animal/ not human/ |
| 61. |  review.pt. |
| 62. |  59 or 60 or 61 |
| 63. |  58 not 62 |

A. Embase

Platform: OvidSP

Database: Ovid Embase 1980-present

Date: 23-08-2011

Limits: no limits were used

Methodological filters: Adverse effect filter: Golder, S. et al Developing efficient search strategies to identify reports of adverse effects in Medline and Embase. Health information and libraries journal (2006),23, p3-12

|  |  |
| --- | --- |
| **Line #** | **Terms** |
| 1. |  exp ETHAMBUTOL/ or ethambutol.mp. |
| 2. |  pyrazinamide.mp. or exp PYRAZINAMIDE/ |
| 3. |  streptomycin.mp. or exp STREPTOMYCIN/ |
| 4. |  amikacin.mp. or exp AMIKACIN/ |
| 5. |  kanamycin.mp. or exp KANAMYCIN/ |
| 6. |  capreomycin.mp. or exp CAPREOMYCIN/ |
| 7. |  viomycin.mp. or exp VIOMYCIN/ |
| 8. |  enviomycin.mp. or exp ENVIOMYCIN/ |
| 9. |  fluoroquinolones.mp. or exp quinolone derivative/ |
| 10. |  levofloxacin.mp. or exp LEVOFLOXACIN/ |
| 11. |  moxifloxacin.mp. or exp MOXIFLOXACIN/ |
| 12. |  ofloxacin.mp. or exp OFLOXACIN/ |
| 13. |  exp CIPROFLOXACIN/ or ciprofloxacin.mp. |
| 14. |  sparfloxacin.mp. or exp SPARFLOXACIN/ |
| 15. |  thioamides.mp. or exp thioamide/ |
| 16. |  cycloserine.mp. or exp CYCLOSERINE/ |
| 17. |  opc-67683.mp. or exp "2,3 dihydro 2 methyl 6 nitro 2 [4 [4 (4 trifluoromethoxyphenoxy) 1 piperidinyl]phenoxymethyl]imidazo[2,1 b]oxazole"/ |
| 18. |  PA-824.mp. or exp "6,7 dihydro 2 nitro 6 (4 trifluoromethoxybenzyloxy) 5h imidazo[2,1 b][1,3]oxazine"/ |
| 19. |  thiacetazone.mp. or exp thioacetazone/ |
| 20. |  p-aminosalicylic acid.mp. or exp aminosalicylic acid/ |
| 21. |  para-aminosalicyclic acid.mp. |
| 22. |  ethionamide.mp. or exp ETHIONAMIDE/ |
| 23. |  rifabutin.mp. or exp RIFABUTIN/ |
| 24. |  rifapentine.mp. or exp RIFAPENTINE/ |
| 25. |  r207910.mp. or exp "1 (6 bromo 2 methoxy 3 quinolinyl) 4 dimethylamino 2 (1 naphthyl) 1 phenyl 2 butanol"/ |
| 26. |  terizidone.mp. or exp TERIZIDONE/ |
| 27. |  protionamide.mp. or exp PROTIONAMIDE/ |
| 28. |  exp CILASTATIN/ or cilastatin.mp. |
| 29. |  TMC207.mp. or exp "1 (6 bromo 2 methoxy 3 quinolinyl) 4 dimethylamino 2 (1 naphthyl) 1 phenyl 2 butanol"/ |
| 30. |  gatifloxacin.mp. or exp GATIFLOXACIN/ |
| 31. |  prothionamide.mp. or exp protionamide/ |
| 32. |  exp contact examination/ |
| 33. |  exp antibiotic prophylaxis/ |
| 34. |  exp chemoprophylaxis/ |
| 35. |  latent.ti,ab. |
| 36. |  contact\*.ti,ab. |
| 37. |  prevent\*.ti,ab. |
| 38. |  prophyla\*.ti,ab. |
| 39. |  ("health care worker" or "health care workers" or ("healthy individual" or "healthy individuals")).ti,ab. |
| 40. |  or/32-39 |
| 41. |  ae.fs. |
| 42. |  to.fs. |
| 43. |  co.fs. |
| 44. |  safe.ti,ab. |
| 45. |  safety.ti,ab. |
| 46. |  side-effect\*.ti,ab. |
| 47. |  undesirable effect\*.ti,ab. |
| 48. |  treatment emergent.ti,ab. |
| 49. |  tolerability.ti,ab. |
| 50. |  toxicity.ti,ab. |
| 51. |  adrs.ti,ab. |
| 52. |  or/41-51 |
| 53. |  or/1-31  |
| 54. |  exp case study/ |
| 55. |  animals/ not humans/ |
| 56. |  review.pt. |
| 57. |  healthy.ti,ab. |
| 58. |  case report/ |
| 59. |  40 or 57 |
| 60. |  53 and 59 |
| 61. |  60 and 52 |
| 62. |  54 or 55 or 56 or 58 |
| 63. |  61 not 62 |